The Missing Link: Roche´s E-Plate VIEW Joins Impedance-based Real-time Monitoring with Visual Inspection of Cells

PENZBERG, Germany--(BUSINESS WIRE)-- The new E-Plate VIEW 96 from Roche (SWX:RO)(SWX:ROG)(Pink Sheets: RHHBY) offers the first time possibility to combine label-free real-time monitoring of cells with visual inspection in one device. E-Plate VIEW 96, a modified version of the E-Plate 96, is a single use, disposable device used for performing cell analysis assays on the Real-Time Cell Analyzer (RTCA) Single Plate (SP) and Multiple Plate (MP) Instruments. It enables for downstream or intermediate visual inspection of cells using microscopes and automated cell imaging systems like Roche’s Cellavista Instrument. Precise quantitative information is provided during all phases of comprehensive experiments about the status of cells: including cell number, cell adhesion, cell viability, and cell morphology. A label or fixation of cells is not needed.

For the modification, four rows of microelectrode sensors were removed in each well to form a “window” for visual inspection. The gold electrode covers approximately 70 % of the bottom area. The E-Plate VIEW 96 has identical outer dimensions as the E-Plate 96 and allows therefore working with both plates in parallel in RTCA SP and MP Instruments without adapters.

“The new E-Plate features an innovative and unique approach that allows combining impedance-based real-time monitoring with visual inspection of cells,” states Ruedi Stoffel, Life Cycle Leader Cellular Analysis of Roche Applied Science. “We expect that in the long run, the xCELLigence System with the E-Plate VIEW will become the platform of choice also for those users currently working with traditional methods such as cell microscopy or end point assays.” According to Stoffel, the new E-Plate formate will find its use mainly in cancer research, in basic research (developmental biology, receptor biology, embryology), in dermatology, and in neurobiology.

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2009, Roche had over 80’000 employees worldwide and invested almost 10 billion Swiss francs in R&D. The Group posted sales of 49.1 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.

For life science research only. Not for use in diagnostic procedures.

XCELLIGENCE is a trademark of Roche.
E-PLATE and ACEA BIOSCIENCES are registered trademarks of ACEA Biosciences, Inc. in the US
Other brands or product names are trademarks of their respective holders.



CONTACT:

Roche Diagnostics
Dr. Burkhard Ziebolz
Phone: +49 8856 604830
Email: [email protected]

KEYWORDS:   United States  Europe  North America  Germany  Switzerland

INDUSTRY KEYWORDS:   Stem Cells  Health  Biotechnology  Genetics  Medical Devices  Oncology  Pharmaceutical  Research  Medical Supplies  Science

MEDIA:

Logo
 Logo

Suggested Articles

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.

At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.